Neoleukin Therapeutics Earnings History image   This NLTX earnings history page last updated 11/17/2023
Neoleukin Therapeutics Earnings History Chart
PeriodEarnings DateGAAP
Q3 202311/14/2023-0.410
Q2 20238/10/2023-0.200
Q1 20235/8/2023-0.200
Q4 20223/20/2023-1.200
Q3 202211/14/2022-1.200
Q2 20228/9/2022-1.400
Q1 20225/9/2022-0.280
Q4 20213/1/2022-0.270
Q3 202111/4/2021-1.400
Q2 20218/5/2021-1.350
Q1 20215/12/2021-1.350
Q4 20203/25/2021-1.150
Q3 202011/9/2020-0.950
Q2 20208/12/2020-1.000
Q1 20205/6/2020-0.900
Q4 20193/12/2020-0.300
Q3 201911/13/2019-2.200
Q2 20197/31/20190.000
Q1 20195/7/2019-0.450
Q4 20183/7/2019-1.000
Q3 201811/7/2018-3.200
Q2 20188/8/20180.600
Q1 20185/8/2018-3.100
Q4 20173/12/2018-3.450
Q3 201711/8/2017-2.500
Q2 20178/8/2017-2.950
Q1 20175/9/2017-1.800
Q4 20163/9/2017-2.400
Q3 201611/9/2016-2.300
Q2 20168/4/2016-3.150
Q1 20165/10/2016-1.950
Q4 20153/14/2016-1.350
Q3 201511/10/2015-2.150
Q2 20158/6/2015-2.200
Q1 20155/12/2015-3.000
Neoleukin Therapeutics Revenue History Chart
PeriodEarnings DateGAAP
Q3 202311/14/2023NA
Q2 20238/10/2023NA
Q1 20235/8/2023NA
Q4 20223/20/2023NA
Q3 202211/14/2022NA
Q2 20228/9/2022NA
Q1 20225/9/2022NA
Q4 20213/1/2022NA
Q3 202111/4/2021NA
Q2 20218/5/2021NA
Q1 20215/12/2021NA
Q4 20203/25/2021NA
Q3 202011/9/2020NA
Q2 20208/12/2020NA
Q1 20205/6/2020NA
Q4 20193/12/2020NA
Q3 201911/13/2019NA
Q2 20197/31/2019NA
Q1 20195/7/2019NA
Q4 20183/7/2019NA
Q3 201811/7/2018NA
Q2 20188/8/20180.03B
Q1 20185/8/2018NA
Q4 20173/12/2018NA
Q3 201711/8/2017NA
Q2 20178/8/2017NA
Q1 20175/9/2017NA
Q4 20163/9/2017NA
Q3 201611/9/2016NA
Q2 20168/4/2016NA
Q1 20165/10/2016NA
Q4 20153/14/2016NA
Q3 201511/10/2015NA
Q2 20158/6/2015NA
Q1 20155/12/2015NA
Quotes delayed 20 minutes

Email EnvelopeFree NLTX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options

Next Earnings Date Calendar:

Atkore (ATKR): 11/17/2023 6:00 AM
Spectrum Brands Holdings (SPB): 11/17/2023 6:30 AM
BJ's Wholesale Club (BJ): 11/17/2023 6:45 AM
Buckle (BKE): 11/17/2023 6:50 AM
Destination XL Group (DXLG): 11/17/2023 7:00 AM
Twist Bioscience (TWST): 11/17/2023 7:30 AM
Leonardo DRS (DRS): 11/18/2023 After close
Vitesse Energy (VTS): 11/20/2023 1:18 AM
GE HealthCare Techs (GEHC): 11/20/2023 2:01 AM
Central Garden & Pet (CENTA): 11/20/2023 After close

More from the Next Earnings Dates Calendar

Earnings History:

UGI (UGI): 11/16/2023 5:20 PM
Post Hldgs (POST): 11/16/2023 5:00 PM
Geospace Technologies (GEOS): 11/16/2023 After close
Compass Minerals Intl (CMP): 11/16/2023 After close
Beazer Homes USA (BZH): 11/16/2023 After close
Matthews International (MATW): 11/16/2023 After close
ESCO Technologies (ESE): 11/16/2023 After close
Gap (GPS): 11/16/2023 After close
Dolby Laboratories (DLB): 11/16/2023 After close
Natural Grocers (NGVC): 11/16/2023 After close

More from the Earnings History archive
Neoleukin Therapeutics (NLTX) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

NMRA Past Earnings
NMTC Past Earnings
NMTR Past Earnings
NOTV Past Earnings
NOVN Past Earnings
NPCE Past Earnings
NRBO Past Earnings
NRC Past Earnings
NRIX Past Earnings
NSTG Past Earnings
On this page we presented the NLTX earnings and revenue history archive for Neoleukin Therapeutics, comparing the historical top line revenue performance quarter by quarter, as well as the NLTX earnings per share history. Any self directed investor doing their due diligence on NLTX (or any other given stock) can benefit from researching all of the Neoleukin Therapeutics past earnings and revenue results going backwards in time, and to help you with this Neoleukin Therapeutics earnings history research, on this page we presented each quarter's resulting numbers in both table and graphical form for easy comparison. Studying these numbers can help an investor by providing important context with which to think about NLTX's next earnings report. In your continued research on Neoleukin Therapeutics we hope you will be sure to check out the further links included for earnings surprises as well as next earnings dates for NLTX. Thanks for visiting, and the next time you need to research NLTX earnings history (or the earnings history of another stock), we hope you'll think of our site as your go-to earnings history research resource of choice.

Recommended: GPT YTD Return, EES Average Annual Return, Funds Holding FPRX.

 

Neoleukin Therapeutics Earnings History | www.NextEarningsDate.com | Copyright © 2020 - 2023, All Rights Reserved

Nothing in NextEarningsDate.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.